the oral hygiene market is evolving...
Oral hygiene is the practice for ensuring disease and other oral health problems are avoided, through the regular brushing of teeth, and cleaning in between the teeth. It is important that oral hygiene is carried out on a regular basis to enable prevention of dental disease and bad breath. Most oral health conditions are largely preventable and can be treated in their early stages.
Growth in the oral hygiene market is mainly focused around two main categories: toothpastes and mouthwashes. The global oral hygiene market size was valued at USD 31.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2021 to 2028.
Oral hygiene market trends are largely driven by an increased consumer interest in health and wellbeing, and a greater understanding of the contributing factors of dental disease. An increased focus on consumer hygiene was also noted after the coronavirus pandemic with patients now opting for at-home dental remedies and preventative measures. Trends such as claiming several effects including anti-caries, anti-gum disease, anti-tartar, breath freshening, tooth whitening and reduction of hypersensitivity are widely driving consumer choice.
Natural and vegan oral health options are also consumer choice driving factors, with differentiated products required to maintain premium positioning within this market. Our oral hygiene differentiated product portfolio offers a wide range of superior attributes to meet the product premiumisation trends. Our extensive technical expertise can help you optimise the performance and get the best results out of your formulation development work. Our speciality chemicals provide superior attributes, such as reduced gum sensitivity, exceptional foam production and offer natural benefits, which are paramount within the oral health market.
Oral hygiene market trends are largely driven by an increased consumer interest in health and wellbeing, and a greater understanding of the contributing factors of dental disease. An increased focus on consumer hygiene was also noted after the coronavirus pandemic with patients now opting for at-home dental remedies and preventative measures. Trends such as claiming several effects including anti-caries, anti-gum disease, anti-tartar, breath freshening, tooth whitening and reduction of hypersensitivity are widely driving consumer choice.
Natural and vegan oral health options are also consumer choice driving factors, with differentiated products required to maintain premium positioning within this market. Our oral hygiene differentiated product portfolio offers a wide range of superior attributes to meet the product premiumisation trends. Our extensive technical expertise can help you optimise the performance and get the best results out of your formulation development work. Our speciality chemicals provide superior attributes, such as reduced gum sensitivity, exceptional foam production and offer natural benefits, which are paramount within the oral health market.
Consumer Health formulation solutions
8.0 MB
Login to download
Download
PRODUCT USE CASE STUDY
Oral mouthwash: "We want a mouthwash without the flavours and colours, but that works"
Technical barriers:
- Surfactants need minimal to no taste
- Surfactants need to have minimal colour
- Surfactants need to cleanse sufficiently
- Surfactants need to be minimal foaming.
Solutions:
- Super Refined™ P35 Castor Oil offers cleaning properties with minimal background taste
- Synperonic™ PE/F 127 is low foaming surfactant with little to no taste
- Both Super Refined™ P35 Castor Oil and Synperonic™ PE/F 127 produce colourless solutions even at high concentration
After formulating with Super Refined™ P35 Castor Oil and the customer was able to make the following pack claims:
- Flavour Free
- Colour Free.
Did you know Synperonic™ PE/F 127 has been shown to be antimicrobial?
Learn more about our oral hygiene solutions
3 items available
Explore recent blogs:
New Research Professor MSO in Vaccine Adjuvants at Statens Serum Institut Copenhagen, Denmark
PRESS RELEASE: Croda Pharma is happy to announce that Dennis Christensen, PhD, Head of Global Research and Development for Vaccine Adjuvant Systems, has been appointed as a part-time Research...
Croda Pharma launches a new bioprocessing solution for shear stress in mammalian cell culture
Croda Pharma has announced the launch of Super Refined™ Poloxamer 188, an innovative bioprocessing solution developed to meet the increasing demands of biopharmaceutical development.